Genmab AS Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Genmab AS are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genmab AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Genmab AS is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 17.30 | |
| Fifty Two Week Low | 12.10 | |
| Fifty Two Week High | 19.00 |
Genmab |
Genmab AS Relative Risk vs. Return Landscape
If you would invest 0.00 in Genmab AS on January 24, 2024 and sell it today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment over 90 days. Genmab AS is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Genmab, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genmab AS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Genmab AS, and traders can use it to determine the average amount a Genmab AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GMXAY |
Based on monthly moving average Genmab AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding Genmab AS to a well-diversified portfolio.
Genmab AS Fundamentals Growth
Genmab Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Pink Sheet performance.
| Return On Equity | 18.38 | |||
| Return On Asset | 8.3 | |||
| Profit Margin | 45.85 % | |||
| Current Valuation | 11.19 B | |||
| Shares Outstanding | 615.13 M | |||
| Price To Earning | 52.09 X | |||
| Price To Book | 10.02 X | |||
| Price To Sales | 22.59 X | |||
| Revenue | 438.84 M | |||
| EBITDA | 224.7 M | |||
| Cash And Equivalents | 921.63 M | |||
| Cash Per Share | 1.50 X | |||
| Debt To Equity | 2.40 % | |||
| Book Value Per Share | 1.80 X | |||
| Cash Flow From Operations | 165.98 M | |||
| Earnings Per Share | 0.36 X | |||
| Total Asset | 4.35 B | |||
| Retained Earnings | (3.96 B) | |||
| Current Asset | 4.14 B | |||
| Current Liabilities | 419 M |
Things to note about Genmab AS performance evaluation
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genmab AS is not yet fully synchronised with the market data | |
| Genmab AS has some characteristics of a very speculative penny stock | |
| Genmab AS has a very high chance of going through financial distress in the upcoming years |
- Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
- Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab AS's pink sheet. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Genmab Pink Sheet
If you are still planning to invest in Genmab AS check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genmab AS's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |